α-酮戊二酸脱氢酶是急性髓系白血病的治疗脆弱点
该研究探讨α-酮戊二酸(αKG)代谢是否为急性髓系白血病(AML)的特异性脆弱点。利用功能基因组学、代谢组学和小鼠模型,发现αKG脱氢酶复合物(催化αKG转化为琥珀酰辅酶A)在多种不良风险AML模型中构成分子依赖;抑制OGDH(该复合物的E1亚基)可损害AML进展并驱动分化。机制上,阻碍αKG经三羧酸循环通量导致天冬氨酸池快速耗竭并阻断从头核苷酸生物合成,而细胞生物能量学基本保留。
要点
- αKG脱氢酶复合物在多种不良风险AML模型中构成分子依赖。
- 抑制OGDH可损害AML进展并驱动分化。
- 机制涉及天冬氨酸耗竭和核苷酸合成阻断,生物能量学基本保留。
核心结论
- αKG脱氢酶复合物(尤其OGDH)是AML的代谢脆弱点,可能成为癌症特异性治疗靶点。
研究设计与样本
- 研究采用功能基因组学、代谢组学和小鼠模型,在多种不良风险AML模型中探究αKG代谢依赖性。
主要发现
- 抑制OGDH(αKG脱氢酶复合物E1亚基)可损害AML进展并驱动分化。
- 阻碍αKG经三羧酸循环通量导致天冬氨酸池快速耗竭并阻断从头核苷酸生物合成,而细胞生物能量学基本保留。
- OGDH抑制后αKG水平升高,影响其他关键氨基酸的生物合成。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Perturbations in intermediary metabolism contribute to the pathogenesis of acute myeloid leukemia (AML) and can produce therapeutically actionable dependencies. Here, we probed whether α-ketoglutarate (αKG) metabolism represents a specific vulnerability in AML. Using functional genomics, metabolomics, and mouse models, we identified the αKG dehydrogenase complex, which catalyzes the conversion of αKG to succinyl coenzyme A, as a molecular dependency across multiple models of adverse-risk AML. Inhibition of 2-oxoglutarate dehydrogenase (OGDH), the E1 subunit of the αKG dehydrogenase complex, impaired AML progression and drove differentiation. Mechanistically, hindrance of αKG flux through the tricarboxylic acid (TCA) cycle resulted in rapid exhaustion of aspartate pools and blockade of de novo nucleotide biosynthesis, whereas cellular bioenergetics was largely preserved. Additionally, increased αKG levels after OGDH inhibition affected the biosynthesis of other critical amino acids. Thus, this work has identified a previously undescribed, functional link between certain TCA cycle components and nucleotide biosynthesis enzymes across AML. This metabolic node may serve as a cancer-specific vulnerability, amenable to therapeutic targeting in AML and perhaps in other cancers with similar metabolic wiring.
引用
- Millman SE, Chaves-Perez A, Janaki-Raman S, et al. α-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia. Blood. 2025. PMID: 39791576. doi:10.1182/blood.2024025245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。